# KLOW FAQ — Common Questions About the Four-Peptide Research Blend > Direct answers to the most common questions about KLOW safety, components, regulatory status, and what the research literature actually shows. If you came here from a search about KLOW safety, your question is probably below. Every answer cites the underlying research. ## Is the KLOW blend safe? The honest answer is that the safety of the four-peptide KLOW blend in humans is unknown. No combination safety study has been published in any species [19]. What exists is single-agent literature for each component — and those records are uneven: favorable preclinical toxicology for BPC-157 in four species [1], a topical human RCT and broad in-vitro safety data for GHK-Cu [6][7], a Phase 1 intravenous trial of full-length Thymosin Beta-4 (not the TB-500 fragment) in 40 healthy volunteers [10], and rodent-only data for KPV [13]. Short-term single-agent exposures of the individual components have a generally favorable signal in the contexts that have been studied. The combination, long-term use, and real-world reconstitution from research-peptide vials are uncharacterized. ## What does the research say about KLOW blend safety? The research says almost nothing about the blend specifically. A literature search returns zero peer-reviewed pharmacology, pharmacokinetic, or safety studies of GHK-Cu + BPC-157 + TB-500 + KPV co-administered [19]. Vendor claims about additive or synergistic effects are extrapolations from single-agent data, not direct combination evidence. The 2025 review on therapeutic peptide drug-drug interactions explicitly notes that current peptide DDI methodology is underdeveloped — meaning the analytical tools required to characterize a four-peptide blend's behavior are themselves still being built. The body of work that does exist describes each component on its own. ## Has KLOW been tested in human clinical trials? No. The KLOW blend has never been tested in a human clinical trial. None of its four components is FDA-approved for systemic human therapeutic use. Among the components: GHK-Cu has been studied in topical clinical trials [6]; full-length Thymosin Beta-4 (the parent protein of TB-500 — not the same molecule) has been in Phase 1 intravenous trials [10] and Phase 2 ophthalmic trials [11]; BPC-157 has fewer than 30 published human subjects across pilot studies [5][18]; KPV has no published human trial of any kind. None of those individual programs constitutes a clinical trial of the blend. ## What are the known side effects of KLOW components? Component-by-component, in the contexts that have been studied: - **BPC-157.** Rodent preclinical toxicology identified no test-related toxic effects, no genotoxicity, no teratogenicity, and no anaphylactic reactions [1]. The human safety record is too small for meaningful adverse event characterization [5]. - **GHK-Cu.** Topical use is generally well tolerated; transient irritation is occasionally reported; rare allergic reactions occur [6]. - **TB-500 / full-length Tβ4.** Phase 1 intravenous Tβ4 reported mild to moderate adverse events with no dose-limiting toxicity at doses up to 1260 mg [10]. The TB-500 fragment specifically has essentially no published human safety data. - **KPV.** No human safety data. Rodent colitis work shows a clean signal in those models [13][14]. What is not captured in any of these single-agent records: how the four components behave together, or what chronic exposure does over many months. ## What does the FDA say about KLOW and its components? The FDA has not addressed the KLOW blend by name. It has addressed BPC-157, which is classified as a Category 2 bulk drug substance — Substances with Safety Concerns — and is explicitly ineligible for pharmacy compounding into human medications. The agency cited lack of human safety data, potential immune reactions, and manufacturing impurities as part of its rationale [17]. GHK-Cu is permitted in topical cosmetics; its injectable form is not FDA-approved for any indication. TB-500 is an unapproved investigational compound. KPV is an unapproved research chemical. A blend that includes BPC-157 inherits BPC-157's Category 2 status. ## Are there any combination safety studies for KLOW? No. A search of the peer-reviewed literature returns zero combination studies — pharmacology, pharmacokinetics, safety, efficacy, or otherwise — for the four-peptide blend [19]. This is one of the central facts of the KLOW evidence picture. Every claim about how the four peptides work together is an inference from how they work individually, applied to a setting that has not been tested. ## How is KLOW different from the individual peptides studied separately? It is different in three ways that matter for safety reading. First, it is a fixed mass ratio. The individual peptides have been studied at doses chosen by the investigators of each study. The KLOW vial's 50:10:10:10 mg ratio was chosen by the vendor for product formulation, not by clinical trial protocol. Second, it is a single reconstitution. All four peptides go into the same vial of bacteriostatic water at the same time, which is a context none of the single-agent stability studies tested. Third, it is administered together. None of the published single-agent pharmacokinetic work characterized clearance, distribution, or interaction in the presence of three other peptides. ## What is unknown about KLOW safety? Most of the safety questions that matter for a real-world research-peptide blend are unanswered. There is no combination study in any species [19]. There is no long-term (>6 month) data on any single component. There is no carcinogenicity data, no reproductive or developmental toxicity data, and no drug-drug interaction data for the blend. Human safety data for the TB-500 7-amino-acid fragment specifically is essentially absent [12]. Human safety data for KPV is entirely absent [13]. The human BPC-157 safety record amounts to fewer than 30 published subjects [5][18]. The blend itself has never been studied in any controlled context. ## What's the regulatory status of each KLOW component? **BPC-157.** FDA Category 2 (Substances with Safety Concerns); ineligible for pharmacy compounding [17]. WADA Prohibited List category S0 [22]. Not approved for human consumption. **GHK-Cu.** Permitted in topical cosmetics. Injectable form not FDA-approved for any indication. Research chemical outside of topical cosmetic use. **TB-500.** Not FDA-approved. WADA Prohibited List category S2. Distinct from full-length Thymosin Beta-4, which has been studied in clinical trials but is also not approved. **KPV.** Not FDA-approved. No specific WADA listing as of the current Prohibited List; the S0 catch-all may apply for athletes. Research chemical only. ## Why is BPC-157 prohibited from compounding pharmacies? The FDA placed BPC-157 on its Category 2 list (Substances with Safety Concerns) under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The agency cited three concerns specifically: insufficient human safety data, the potential for immune reactions, and manufacturing impurities in the bulk material [17]. The Category 2 placement makes BPC-157 ineligible for compounding into human medications by traditional 503A compounding pharmacies or 503B outsourcing facilities — meaning a licensed compounding pharmacy cannot legally prepare BPC-157 for human use. The substance remains available as a research chemical for non-human laboratory investigation. ## What is the difference between TB-500 and full-length Thymosin Beta-4? Full-length Thymosin Beta-4 (Tβ4) is a 43-amino-acid endogenous peptide. It is the molecule that has been studied in human Phase 1 intravenous trials [10] and Phase 2 ophthalmic trials [11] — and it is the basis of clinical-trial compounds RGN-259 and RGN-352. TB-500 is a synthetic 7-amino-acid peptide (LKKTETQ) that corresponds to the actin-binding region of Tβ4. It retains the actin-binding activity that drives the cell-migration mechanism [12], but it is roughly one-sixth the length of the parent protein and lacks most of its sequence. Clinical safety data for full-length Tβ4 does not transfer cleanly to the TB-500 fragment. The two are often conflated in product marketing and in popular write-ups, but they are different molecules with different evidence bases. ## Why does GHK-Cu have more human data than the other three? GHK-Cu's history runs longer and through a different application path. The tripeptide was identified in human plasma in the 1970s, with the observation that its concentration declines with age. Most of the clinical work that followed has been topical — cosmetic and wound-healing applications — because the topical route does not require systemic regulatory approval and because the molecule's short plasma half-life makes systemic administration challenging [6][8]. The diabetic foot ulcer trial showing 40% improved wound closure and 27% reduced infection rates was published in 1994 [6]; topical cosmetic studies have continued in the decades since. None of this clinical experience extends to injectable GHK-Cu, which is the form used in research-peptide blends. The human dataset is real but narrow — it is for the topical form of the molecule. ## Are the four peptides synergistic when combined? There is no published evidence to answer this question. No peer-reviewed pharmacology study has tested the four components together [19]. Synergy claims circulating around the KLOW blend are vendor inferences from single-agent mechanism, not findings from co-administration studies. Mechanistic overlap exists — BPC-157 and Tβ4 both have angiogenic activity, KPV and GHK-Cu both have anti-inflammatory activity — but mechanistic overlap is not synergy. It can produce additive effects, ceiling-bounded effects, receptor-competition attenuation, or entirely novel interaction effects. Determining which of those a real combination produces requires direct testing. That testing has not been done. ## What does WADA say about KLOW for athletes? WADA's Prohibited List addresses individual substances, not vendor product names. Two of the four KLOW components are explicitly prohibited: BPC-157 is on category S0 (Non-Approved Substances) and is prohibited at all times, with no eligibility for Therapeutic Use Exemption [22]; TB-500 is on category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and is prohibited at all times. GHK-Cu and KPV have no specific listing, though the S0 catch-all for investigational peptides may apply. An athlete using a product containing BPC-157 or TB-500 is using a prohibited substance for WADA-tested sport. ## Is KLOW legal? Legality of research peptides varies by jurisdiction and by intended use. In the United States, GHK-Cu is permitted in topical cosmetics; injectable GHK-Cu, BPC-157, TB-500, and KPV are unapproved drugs that are not legal to sell, market, or distribute for human consumption. BPC-157 is specifically ineligible for pharmacy compounding into human medications under FDA Category 2 [17]. Research peptides are sold in the United States and elsewhere under 'for research use only' labeling for laboratory and in-vitro use. None of the four KLOW components is approved for systemic human therapeutic use anywhere in the world. This site is not legal advice. --- Editorial commentary on peer-reviewed research — not a clinic, not a vendor, not a prescription.